在心力衰竭中调节RNAs
Clarissa Pedrosa Costa Gomes1, Blanche Schroen2, Gabriela M Kuster3
1Cardiovascular Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg (C.P.d.C.G., Y.D.).
Circulation
|January 28, 2020
概括
调节性RNAs (regRNAs),包括信使RNAs和非编码RNAs,对于心力衰竭中的基因表达至关重要. 了解它们的作用可能会导致心血管疾病的新诊断和治疗策略.
科学领域:
- 心血管生物学
- 分子遗传学
- RNA生物学
背景情况:
- 心血管疾病,尤其是心力衰竭,
- 基因表达的调节对于维持心脏平衡至关重要.
- 编码和非编码的RNA分子在这种调节中起着关键作用.
研究的目的:
- 扩大调控RNA (regRNA) 的概念,包括蛋白质编码和非编码RNA.
- 审查心力衰竭中各种regRNAs的调节和功能.
- 探索regRNAs在诊断,预后和治疗心力衰竭方面的潜力.
主要方法:
- 关于调节性RNA的现有研究的文献审查和综合.
- 对信使RNA,微RNA,长非编码RNA和圆形RNA在心力衰竭中的作用进行分析.
- 对regRNA研究的临床实用性和未来方向的讨论.
主要成果:
- 调控性RNA (regRNAs) 包括影响基因表达的编码和非编码RNA分子.
- 特定的regRNAs,包括mRNAs,miRNAs,lncRNAs和circRNAs,都与心力衰竭的病理生理学有关.
- 这些regRNA具有作为心血管疾病生物标志物和治疗点的潜力.
结论:
- 调节性RNA的定义应该扩展到所有参与基因表达控制的RNA物种.
- 信息RNA,微RNA,长非编码RNA和圆形RNA是心力衰竭的发展和进展的组成部分.
- 对regRNA的进一步研究有望促进心力衰竭的诊断和治疗.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
842
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
842
01:29Heart Failure II: Pathophysiology
603
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
603
01:30Heart Failure V: Medical Management
166
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
166
01:31Regulation of Heart Rates
3.6K
The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
3.6K
01:17Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
01:22Heart Failure Drugs: β-Blockers
697
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
697